| Dr Jacob Lee Spain, MD | |
|
1235 E Cherokee St, Springfield, MO 65804-2203 | |
| (417) 820-2000 | |
| Not Available |
| Full Name | Dr Jacob Lee Spain |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1235 E Cherokee St, Springfield, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053513499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 4301087626 (Michigan) | Secondary |
| 207P00000X | Emergency Medicine | 2009003438 (Missouri) | Primary |
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
Resource Ventures, Inc. Interim President Michael Cipolla is pleased to announce today that the company anticipates reporting record annual revenues.
BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.
As a way to help both the sick and their medical care providers to make the best healthcare decisions possible, a special section of the current November/December 2008 issue of Medical Decision Making examines three current evidenced-based theories that can help to improve assessments, assist in prevention programs, and help with intervention efforts.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
› Verified 2 days ago
| Entity Name | Mercy Hospital Springfield |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043242159 PECOS PAC ID: 7416867593 Enrollment ID: O20050118000038 |
News Archive
Resource Ventures, Inc. Interim President Michael Cipolla is pleased to announce today that the company anticipates reporting record annual revenues.
BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.
As a way to help both the sick and their medical care providers to make the best healthcare decisions possible, a special section of the current November/December 2008 issue of Medical Decision Making examines three current evidenced-based theories that can help to improve assessments, assist in prevention programs, and help with intervention efforts.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jacob Lee Spain, MD 1235 E Cherokee St, Springfield, MO 65804-2203 Ph: (417) 820-2000 | Dr Jacob Lee Spain, MD 1235 E Cherokee St, Springfield, MO 65804-2203 Ph: (417) 820-2000 |
News Archive
Resource Ventures, Inc. Interim President Michael Cipolla is pleased to announce today that the company anticipates reporting record annual revenues.
BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.
As a way to help both the sick and their medical care providers to make the best healthcare decisions possible, a special section of the current November/December 2008 issue of Medical Decision Making examines three current evidenced-based theories that can help to improve assessments, assist in prevention programs, and help with intervention efforts.
Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
› Verified 2 days ago
Janel M Ochse, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2000 | |
Gregory J Kutter, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3801 S National Ave, Springfield, MO 65807 Phone: 417-269-6583 Fax: 417-269-6573 | |
Douglas Scott Ham, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1423 N Jefferson Ave, Springfield, MO 65802 Phone: 417-269-6583 Fax: 417-269-6573 | |
Daryl Thomas Steen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2000 | |
Dr. David Darmsteadter, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2115 | |
Amanda Jo Dinsmore, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2000 |